PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Prestige Consumer Healthcare (NYSE: PBH)
›
Prestige Consumer Healthcare (NYSE: PBH) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 890 employees.
The shares were at 49.60 USD on 19 November 2026, down 17.3% over 52 weeks. Its 52-week range is 41.77 USD to 71.07 USD: the price is 30.2% below the high and 18.7% above the low.
At a market capitalisation of 2.35B USD, it trades at 15.3 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 38% for PBH.
Prestige Consumer Healthcare reports return on equity of 10.1%, an operating margin of 26.4% and revenue up 22.7% year over year.
Its debt exceeds its cash by 2.08B USD, a debt-to-equity ratio of 0.55. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 66.20 USD is 33.5% above the current price. The next earnings report is expected on 4 February 2027.